// App-Quantinova.ai

: Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study

Researchers

Presenter

  • Richard Greil

Principal Investigators

  • Graeme Fraser

  • Brian Leber

  • Reinhard Marks

  • Giulia Quaresmini

  • Jan Moritz Middeke

  • Gianpietro Semenzato

  • William Schary

  • Michelle Boyer

  • Madlaina Breuleux

  • Noelle Crompton

  • Kathryn Humphrey

  • Paula Marlton

Medical Centers

  • Department of Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Paracelsus Medical University Salzburg, and Salzburg Cancer Research Institute and Cancer Cluster Salzburg,Salzburg,Austria

  • Department of Oncology, McMaster University, Hamilton, Canada

  • Clinical Pathology, McMaster University, Hamilton, Canada

  • Klinik für Innere Medizin I, Hämatologie, Onkologie und Stammzelltransplantation, Universitäts Klinikum Freiburg,Freiburg,Germany

  • Rheumatology Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy

  • Medizinische Klinik und Poliklinik I, TU Dresden, Dresden, Germany

  • Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Padua, Italy

  • AbbVie, Inc., North Chicago, IL

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Division of Cancer Services, Princess Alexandra Hospital, and Faculty of Medicine University of Queensland,Brisbane,Australia

Locations

  • Austria

  • Canada

  • Germany

  • Italy

  • United States

  • United Kingdom

  • Switzerland

  • Australia

Companies

  • Feng Chi Biotech Cor

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Chronic Lymphocytic Leukemia

  • Arrhythmia

  • Neutropenia

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Biaxin

  • Bendamustine

  • fludarabine tablet

  • Venetoclax

  • Ibrutinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02005471

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved